Aigen Investment Management’s Quest Diagnostics DGX Stock Holding History

Aigen Investment Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,414	Closed	-$1.15M	–	862
2025 Q2	$1.15M	Buy	+6,414	New	+$1.11M	0.16%	208
2024 Q4	–	Sell	-2,216	Closed	-$344K	–	792
2024 Q3	$344K	Sell	2,216 -1,093	-33%	-$163K	0.07%	426
2024 Q2	$453K	Sell	3,309 -13,756	-81%	-$1.88M	0.09%	340
2024 Q1	$2.27M	Buy	+17,065	New	+$2.21M	0.49%	33
2023 Q4	–	Sell	-7,608	Closed	-$927K	–	851
2023 Q3	$927K	Buy	7,608 +5,879	+340%	+$783K	0.17%	180
2023 Q2	$243K	Buy	+1,729	New	+$238K	0.04%	557
2022 Q1	–	Sell	-14,476	Closed	-$2.35M	–	672
2021 Q4	$2.35M	Buy	+14,476	New	+$2.2M	0.14%	185
2020 Q2	–	Sell	-12,246	Closed	-$983K	–	927
2020 Q1	$983K	Buy	+12,246	New	+$1.27M	0.13%	217

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aigen Investment Management's DGX Position: Q3 2025 in Review

Aigen Investment Management sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 6,414 shares — an estimated $1.15M sold.

Aigen Investment Management first reported a position in DGX in Q1 2020 and held it in 8 quarters. The position peaked at $2.35M in Q4 2021. 1,005 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

Aigen Investment Management reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
Aigen Investment Management sold 6,414 Quest Diagnostics shares in Q3 2025, an estimated $1.15M.
Aigen Investment Management first reported a position in Quest Diagnostics in Q1 2020 and held it in 8 quarters.
Aigen Investment Management's Quest Diagnostics position peaked at $2.35M in Q4 2021.
1,005 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Aigen Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.